The Filing Desk

Scilex vs Verastem

Scilex SCLX · Verastem VSTM · Pharmaceuticals

Verastem reported revenue of $31 million in fiscal 2025, about the same as Scilex's $30 million in fiscal 2025. Scilex's revenue fell 46.5% in its latest year, and Verastem's grew 209.1%. Scilex had an operating margin of -1143.7%, against -550.3% at Verastem.

Side by side

ScilexVerastem
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$30M$31M
Revenue growth−46.5%209.1%
Revenue growth a year, last 5 years5.1%−19.0%
Gross margin——
Operating margin−1,143.7%−550.3%
Net margin−1,236.4%−677.6%
Free cash flow$4M—
Free cash flow margin12.2%—
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count108,662.9%94.1%
Last close$0.65$6.86
P/E at the last close——
Insider trades, last 12 monthssold $12.8 millionsold $680,195
Piotroski F-score3 of 9—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
ScilexVerastem
Operating margin
Percent of revenue
ScilexVerastem
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
ScilexVerastem

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Scilex and Verastem pages.